Navigating the Changing Landscape in AML: Key Considerations in Treatment Delivery
Please complete Pre-test
Chapter 1 of 2
Release Date: June 16, 2021
Expiration Date: June 16, 2022
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
The inclusion of new therapies has augmented the treatment paradigm for AML and has sparked a trend toward outpatient therapy, which necessitates the collaboration of a multidisciplinary team, detailed patient assessment, careful preparation of therapy, and thorough patient monitoring. In this way, successful outpatient administration of treatment for AML may be possible. Recently, MediCom convened a panel of expert faculty in AML to share their experiences and provide practical considerations and guidance for the implementation of an outpatient center for AML therapy. In this activity, three expert faculty present key findings of this consensus, including identification of patients who may be appropriate for outpatient therapy, optimal administration of therapy, and effective implementation of supportive care measures.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Identify criteria by which patients should be assessed to determine eligibility for outpatient induction therapy
- Describe a comprehensive clinical approach to monitoring and managing patients with AML who receive outpatient therapy
- Examine the process for administration of intensive and less intensive induction and consolidation treatment in the outpatient setting for patients with either de novo or secondary AML
- Summarize a patient-centered approach to care that is focused on patient/caregiver education
Chapter 1: The Changing Landscape, Current Therapeutic Regimens, Safety and Feasibility in Moving Chemotherapy to the Outpatient Setting – Chetasi Talati, MD; Harry P. Erba, MD, PhD; Sandra E. Kurtin, PhD, ANP-C, AOCN
Chapter 2: Case Studies – Chetasi Talati, MD; Harry P. Erba, MD, PhD; Sandra E. Kurtin, PhD, ANP-C, AOCN
Instructions for Participation and Credit
This activity is eligible for credit through June 16, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Chetasi Talati, MD
Department of Oncologic Sciences
College of Medicine
University of South Florida
Dr. Chetasi Talati received her medical degree from American University of Antigua College of Medicine (Kasturba Medical College, India). She completed an internal medicine residency at University at Buffalo (SUNY Buffalo), and a hematology and medical oncology fellowship at the University of South Florida and Moffitt Cancer Center. She is an Assistant Professor in the Department of Oncologic Sciences, College of Medicine, at the University of South Florida, and an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center.
Dr. Talati holds memberships in the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Medical Association (AMA), and the American College of Physicians (ACP). She is an ad hoc reviewer for Annals of Internal Medicine, Journal of Cellular and Molecular Medicine, Clinical Medicine Insights: Oncology, Leukemia Research, Therapeutic Advances in Hematology, Cancer, Leukemia & Lymphoma, Blood Cells, and Molecules and Diseases.
Dr. Talati’s clinical interests include management of patients with myeloid malignancies with a focus on acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). Her research interests include optimizing the current prognostic systems and treatment strategies for patients with myeloid malignancies, with particular interest in designing early phase clinical trials for patients with AML.
Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Durham, North Carolina
Dr. Harry Erba received his medical degree and doctorate in biophysics from Stanford University. He completed an internship and residency in internal medicine, as a well as a fellowship in hematology/oncology at the Brigham and Women's Hospital, Harvard Medical School. He is currently Professor of Medicine and is a member of the Division of Hematologic Malignancy and Cellular Therapy at Duke University. In addition, Dr. Erba serves as the Director of the Leukemia Program, as well as Medical Director of the Hematologic Malignancies Inpatient Service.
As an active member in the SWOG (formerly, Southwest Oncology Group) Leukemia Committee for over a decade, Dr. Erba worked closely with the leadership of the SWOG Leukemia, Lymphoma, Myeloma and Bone Marrow Transplant Committees. He has served as the Chairman of the SWOG Leukemia Committee, and serves on the NCI Leukemia Steering Committee.
Dr. Erba has focused on the assessment of novel therapies in acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, and other myeloproliferative neoplasms. He has been involved in numerous clinical trials in these hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs.
Sandra E. Kurtin, PhD, ANP-C, AOCN®
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona Cancer Center
Dr. Sandra Kurtin received her BSN, MS in oncology nursing, post-graduate certification in geriatric and adult practice, and most recently, her PhD in nursing at the University of Arizona. She is an Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona College of Medicine and is a Hematology/Oncology Nurse Practitioner at The University of Arizona Cancer Center.
Dr. Kurtin is a founding board member and treasurer of the Advanced Practitioner Society for Hematology and Oncology (APSHO), as well as a board member of American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), and Oncology Nursing Society (ONS). In addition, she is a member of the executive committee, board of directors and co-chair of the Nursing Leadership Board for the MDS Foundation. Dr. Kurtin is associate editor for The Journal of the Advanced Practitioner in Oncology and is an editorial board member for JCO Clinical Cancer Informatics, The Oncology Nurse, Oncology: Nurse Edition, and the ASCO People Living with Cancer website. She has presented numerous regional, national, and international lectures on oncology related topics and has published numerous articles in peer-reviewed journals including the New England Journal of Medicine, Cancer Nursing, Clinical Leukemia, Blood, Leukemia Research, The Journal of the Advanced Practitioner in Oncology, and The Clinical Journal of Oncology Nursing. Dr. Kurtin’s research focus is on heath technology engagement and communicative health literacy aimed at improving health self-management among older adult cancer survivors and their caregivers.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Jazz Pharmaceuticals.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-029-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-029-145
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Chetasi Talati has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company, speakers’ bureau activities from Astellas Pharma US, Inc. and Jazz Pharmaceuticals plc, as well as consultant fees from Daiichi Sankyo, Inc. and Pfizer Inc.
Dr. Harry Erba has received consultant fees from AbbVie Inc., Agios, Astellas Pharma US, Inc., Celgene Corporation - A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlycoMimetics, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, and Novartis AG, as well as honoraria related to speakers’ bureau activities from AbbVie, Agios, Celgene Corporation - A Bristol-Myers Squibb Company, Incyte, Jazz, and Novartis. He has received grant support related to research activities from AbbVie, Agios, Amgen Inc., Daiichi Sankyo, FORMA Therapeutics, Inc., Forty Seven Inc., GlycoMimetics, ImmunoGen, Inc., Jazz, MacroGenics, Inc., Novartis, and PTC Therapeutics.
Dr. Sandra Kurtin has received honoraria related to formal advisory activities and as a consultant from Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation - A Bristol-Myers Squibb Company, Incyte Corporation, Jazz Pharmaceuticals plc, Novartis AG, Pharmacyclics, Inc., and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.